Adalimumab subsidised in Australia

The Age reports that adalimumab (marketed as Humira) will be listed on the Pharmaceutical Benefits Scheme from next week. This means that Australian Crohn's patients will be able to purchase the drug for a nominal fee.

Previously, the drug's high cost would have kept it out of reach of many people. Although the government is now picking up the tab, there is a net economic benefit to Australia. More Crohn's patients will be able to remain productive members of the workforce instead of relying on disability pensions.

For a behind-the-scenes look at a similar decision I found it interesting to read an advisory note from the Western Australian Therapeutic Advisory Group indicating their economic reasons for recommending subsidising adalimumab.